Transcenta and WuXi Biologics sign HiCB technology licensing and strategic collaboration
Transcenta Therapeutics and WuXi Biologics have entered a strategic licensing collaboration covering Transcenta's HiCB continuous bioprocessing technologies and ExcelPro media platform.
Under the agreement, WuXi Biologics receives a non-exclusive licence to use Transcenta's HiCB technologies, with Transcenta receiving RMB10 million upfront and potential additional milestone payments.
The collaboration broadens commercial access to continuous bioprocessing technology and highlights growing investment in manufacturing productivity across biologics development.
Field | Content |
Alert Type | Technology licensing agreement |
Companies | Transcenta Therapeutics and WuXi Biologics |
Technology | HiCB continuous bioprocessing technologies |
Additional Platform | ExcelPro media |
Licence Type | Non-exclusive |
Upfront Payment | RMB10 million |
Additional Economics | Potential milestone payments |
Industry Area | Biologics manufacturing |
What Happened | Transcenta granted WuXi Biologics a non-exclusive licence to its HiCB technologies and ExcelPro media platform as part of a strategic collaboration. |
Why It Matters | The agreement supports wider adoption of continuous bioprocessing approaches designed to improve biologics manufacturing efficiency and productivity. |
Supporting Context | Transcenta receives RMB10 million upfront and may receive additional milestone payments. |
Key Takeaway | The collaboration commercialises Transcenta's manufacturing technology through one of the world's largest biologics development and manufacturing providers. |
What to Watch | Deployment of HiCB across WuXi Biologics programmes and achievement of future milestones. |
Primary Source | Transcenta Therapeutics / WuXi Biologics |
Relevant Date | September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
댓글